Diabetes: Lixisenatide does not increase rates of CVD events

Nature Reviews Cardiology

Volumn 13, Issue 2, 2016, Pages 63-

  Huynh, Karina ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIXISENATIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME; AGONISTS; DIABETES MELLITUS, TYPE 2; FEMALE; MALE;

ACUTE CORONARY SYNDROME; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PEPTIDES;

EID: 84955407294     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.199     Document Type: Note

References (1)

1. Pfeffer, M. A., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247-2257 (2015)